A short overview of dual targeting HDAC inhibitors

This publication has 21 references indexed in Scilit:

• Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
  European Journal of Medicinal Chemistry, 2024
• Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
  Drug Resistance Updates, 2023
• The application of PROTAC in HDAC
  European Journal of Medicinal Chemistry, 2023
• A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
  European Journal of Medicinal Chemistry, 2023
• Targeting histone deacetylases for cancer therapy: Trends and challenges
  Acta Pharmaceutica Sinica B, 2023
• Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties
  Journal of Medicinal Chemistry, 2022
• Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells
  Journal of Medicinal Chemistry, 2020
• Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet Oncology, 2019
• Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer
  Cancer Cell, 2016
• Epigenetic modification enzymes: catalytic mechanisms and inhibitors
  Acta Pharmaceutica Sinica B, 2013